Emergency and Prophylactic Use of Miniaturized Veno-Arterial Extracorporeal Membrane Oxygenation in Transcatheter Aortic Valve Implantation

作者：Husser Oliver; Holzamer Andreas; Philipp Alois; Nunez Julio; Bodi Vicente; Mueller Thomas; Lubnow Matthias; Luchner Andreas; Lunz Dirk; Riegger Guenter A J; Schmid Christof; Hengstenberg Christian^*; Hilker Michael

来源：Catheterization and Cardiovascular Interventions, 2013, 82(4): E542-E551.

DOI：10.1002/ccd.24806

• transcatheter aortic valve implantation
• extracorporeal membrane oxygenation
• emergency
• prophylactic
• procedural complications

ObjectivesTo report our center%26apos;s experience using veno-arterial extracorporeal membrane oxygenation (vaECMO) in transcatheter aortic valve implantation (TAVI). %26lt;br%26gt;BackgroundIn TAVI, short-term mortality closely relates to life threatening procedural complications. VaECMO can be used to stabilize the patient in emergency situations. However, for the prophylactic use of vaECMO in very high-risk patients undergoing TAVI there is no experience. %26lt;br%26gt;MethodsFrom January 2009 to August 2011, we performed 131 TAVI. Emergency vaECMO was required in 8 cases (7%): ventricular perforation (n=3), hemodynamic instability/cardiogenic shock (n=4), hemodynamic deterioration due to ventricular tachycardia (n=1). Since August 2011, during 83 procedures, prophylactic vaECMO was systematically used in very high-risk patients (n=9, 11%) and emergency ECMO in one case (1%) due to ventricular perforation. %26lt;br%26gt;ResultsMedian logistic EuroScore in prophylactic vaECMO patients was considerably higher as compared to the remaining TAVI population (30% vs. 15%, P=0.0003) while in patients with emergency vaECMO it was comparable (18% vs. 15%, P=0.08). Comparing prophylactic to emergency vaECMO, procedural success and 30-day mortality were 100% vs. 44% (P=0.03) and 0% vs. 44% (P=0.02), respectively. Major vascular complications and rate of life threatening bleeding did not differ between both groups (11% vs. 11%, P=0.99 and 11% vs. 33%, P=0.3) and were not vaECMO-related. %26lt;br%26gt;ConclusionsLife-threatening complications during TAVI can be managed using emergency vaECMO but mortality remains high. The use of prophylactic vaECMO in very high-risk patients is safe and may be advocated in selected cases.

• 出版日期2013-10-1